Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Donald W Light

Showing results (41-50 of 51) with videos related to

Pageof 6
Sort By:
BMJ (Clinical Research Ed.)|August 9, 2012
Pharmaceutical research and development: what do we get for all that money?Donald W Light, Joel R Lexchin
Tidsskrift for Den Norske Laegeforening : Tidsskrift for Praktisk Medicin, Ny Raekke|June 28, 2003
[The new physician's role--quality, openness and confidence]Donald W Light, Olaf Gjerløw Aasland
American Journal of Hematology|September 16, 2018
The "American (cancer) patients first" plan to reduce drug prices-A critical assessmentHagop Kantarjian, Donald W Light, Vivian Ho
Health Affairs (Project Hope)|April 8, 2011
Longer exclusivity does not guarantee better drugsDonald W Light, Joel Lexchin, Jörg Schaaber
Ethnic and Racial Studies|April 16, 2013
Life on the Edge: Immigrants Confront the American Health SystemAlejandro Portes, Patricia Fernández-Kelly, Donald W Light
The Journal of Law, Medicine & Ethics : a Journal of the American Society of Law, Medicine & Ethics|October 4, 2013
Institutional corruption of pharmaceuticals and the myth of safe and effective drugsDonald W Light, Joel Lexchin, Jonathan J Darrow
Cancer|March 20, 2014
The Patient Protection and Affordable Care Act: Is it good or bad for oncology?Hagop M Kantarjian, David P Steensma, Donald W Light
Journal of Health Politics, Policy and Law|July 3, 2003
No exit and the organization of voice in biotechnology and pharmaceuticalsDonald W Light, Ramón Castellblanch, Pablo Arredondo, et al.
Journal of Health Politics, Policy and Law|December 19, 2009
Policy making on data exclusivity in the European Union: from industrial interests to legal realitiesSandra Adamini, Hans Maarse, Esther Versluis, et al.
Vaccine|August 12, 2009
Estimated research and development costs of rotavirus vaccinesDonald W Light, Jon Kim Andrus, Rebecca N Warburton
Pageof 6

Showing results (41-50 of 51) with videos related to

Sort By:
Pageof 6
BMJ (Clinical Research Ed.)|August 9, 2012
Pharmaceutical research and development: what do we get for all that money?Donald W Light, Joel R Lexchin
Tidsskrift for Den Norske Laegeforening : Tidsskrift for Praktisk Medicin, Ny Raekke|June 28, 2003
[The new physician's role--quality, openness and confidence]Donald W Light, Olaf Gjerløw Aasland
American Journal of Hematology|September 16, 2018
The "American (cancer) patients first" plan to reduce drug prices-A critical assessmentHagop Kantarjian, Donald W Light, Vivian Ho
Health Affairs (Project Hope)|April 8, 2011
Longer exclusivity does not guarantee better drugsDonald W Light, Joel Lexchin, Jörg Schaaber
Ethnic and Racial Studies|April 16, 2013
Life on the Edge: Immigrants Confront the American Health SystemAlejandro Portes, Patricia Fernández-Kelly, Donald W Light
The Journal of Law, Medicine & Ethics : a Journal of the American Society of Law, Medicine & Ethics|October 4, 2013
Institutional corruption of pharmaceuticals and the myth of safe and effective drugsDonald W Light, Joel Lexchin, Jonathan J Darrow
Cancer|March 20, 2014
The Patient Protection and Affordable Care Act: Is it good or bad for oncology?Hagop M Kantarjian, David P Steensma, Donald W Light
Journal of Health Politics, Policy and Law|July 3, 2003
No exit and the organization of voice in biotechnology and pharmaceuticalsDonald W Light, Ramón Castellblanch, Pablo Arredondo, et al.
Journal of Health Politics, Policy and Law|December 19, 2009
Policy making on data exclusivity in the European Union: from industrial interests to legal realitiesSandra Adamini, Hans Maarse, Esther Versluis, et al.
Vaccine|August 12, 2009
Estimated research and development costs of rotavirus vaccinesDonald W Light, Jon Kim Andrus, Rebecca N Warburton
Pageof 6